Can-Fite BioPharma Ltd. (TLV:CANF)
1.500
0.00 (0.00%)
Apr 24, 2025, 5:24 PM IDT
Can-Fite BioPharma Employees
Can-Fite BioPharma had 5 employees as of December 31, 2024. The number of employees decreased by 3 or -37.50% compared to the previous year.
Employees
5
Change (1Y)
-3
Growth (1Y)
-37.50%
Revenue / Employee
490.98K ILS
Profits / Employee
-5.74M ILS
Market Cap
58.40M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Teva Pharmaceutical Industries | 35,686 |
Danel (Adir Yeoshua) | 3,961 |
Kamada | 420 |
Bait Bakfar | 228 |
Novolog (Pharm-Up 1966) | 955 |
Ilex Medical | 223 |
BrainsWay | 134 |
SofWave Medical | 126 |
Can-Fite BioPharma News
- 9 days ago - Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite's Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients - GlobeNewsWire
- 12 days ago - Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares - GlobeNewsWire
- 12 days ago - Can-Fite Biopharma GAAP EPS of $0.00, revenue of $0.67M - Seeking Alpha
- 5 weeks ago - Can-Fite Partner Vetbiolix Accelerate Piclidenoson Development with Advanced Clinical Trial for Canine Osteoarthritis in a $3.8 Billion Market - GlobeNewsWire
- 5 weeks ago - Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with Piclidenoson - GlobeNewsWire
- 7 weeks ago - Can-Fite Innovative Publication: Namodenoson in Liver Cancer Treatment Alongside with Cardiac, Liver, and Neurological Benefits - GlobeNewsWire
- 2 months ago - Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on February 25 - GlobeNewsWire
- 2 months ago - Can-Fite BioPharma to Present the Namodenoson Anti-Obesity Effect at BIO CEO & Investor Conference 2025 - GlobeNewsWire